Health News Review

Amidst the daily drumbeat of dreck that we see as we peruse health care news coverage every day, it is refreshing to reflect on the peaks of excellence that rise up above the cacophony.

The Council for the Advancement of Science Writing this year honored John Fauber of the Milwaukee Journal Sentinel and Joanne Silberner with its Victor Cohn Prize for Excellence in Medical Science Reporting.  From the announcement:

The judges were particularly impressed by Silberner’s enterprising December 2012 seven-part series on global cancer issues in Haiti, India and Uganda: “Her sparkling storytelling and the human dimensions in this series are hallmarks of Silberner’s sterling radio career,” they said. The radio series, broadcast on Public Radio International’s “The World,” was an independent multimedia project initiated by Silberner with travel support from the Pulitzer Center on Crisis Reporting.

Fauber was cited for what the judges said was his “dogged, never-give-up” investigative series, dubbed “Side Effects,” on financial conflicts of interest in medical research and health care delivery.

Fauber never takes his foot off the gas pedal, adding a new gem this week, “Developer of acne guidelines largely funded by drug makers.”  We’ve become friends who share ideas regularly.

And I’ve known Silberner for a long time, going back to her NPR days.  What an ambitious project she took on.

On the Knight Science Journalism Tracker, Paul Raeburn wrote: “Congratulations to Fauber and Silberner for reminding us what old-fashioned investigative journalism can do.”

————-

Meantime, Raeburn also lauded the work of Paul Goldberg of The Cancer Letter and Eric Berger and Todd Ackerman of the Houston Chronicle for investigating the question, “Did M.D. Anderson Cancer Center’s president mislead investors about his company’s drug?

Finally, don’t miss a new ProPublica project just published – “Use Only As Directed” – that lists these “major takeways” :

1. About 150 Americans die a year by accidentally taking too much acetaminophen, the active ingredient in Tylenol, federal data from the CDC shows.

2. Acetaminophen has a narrow safety margin: the dose that helps is close to the dose that can cause serious harm, according to the FDA.

3. The FDA has long been aware of studies showing the risks of acetaminophen. So has the maker of Tylenol, McNeil Consumer Healthcare, a division of Johnson & Johnson.

4. Over more than 30 years, the FDA has delayed or failed to adopt measures designed to reduce deaths and injuries from acetaminophen. The agency began a comprehensive review to set safety rules for acetaminophen in the 1970s, but still has not finished.

5. McNeil, the maker of Tylenol, has taken steps to protect consumers. But over more than three decades, the company has repeatedly opposed safety warnings, dosage restrictions and other measures meant to safeguard users of the drug.

———————–

Follow us on Twitter:

https://twitter.com/garyschwitzer

https://twitter.com/healthnewsrevu

and on Facebook.

 

Comments

Greg Pawelski posted on September 24, 2013 at 10:03 am

In regards to Paul Raeburn’s piece “Did M.D. Anderson Cancer Center’s president mislead investors about his company’s drug?, I remember reading back in 2007 about the drug tivozanib (KRN951), a VEGF inhibitor that was supposed to curtail the construction of new blood vessels to a solid tumor thereby suffocating it, but did not address the cause of the cancer itself. AVEO was trying to build out a clinical-stage portfolio of targeted therapies intended to serve major unmet medical needs in cancer. It acquired from Kirin Brewery Co., Ltd. an exclusive license to develop and commericalize tivozanib. However, investigators recognized that first generation inhibitors may be sub-optimal in important respects. In a 30-patient Phase I clinical trial in patients with advanced solid tumors in which the maximum tolerated dose of tivozanib had been established, found that of seven patients with refractory renal cell carcinoma enrolled to date, all have achieved either a partial response or stable disease as defined by the trial protocol, with one patient exhibiting a response lasting more than 2.5 years (7 out of 7 success isn’t bad?). In a press release statement, the President of Pharmaceutical Division, Kirin Brewery Co., Ltd. said back then, Although Kirin had the opportunity to partner KRN951 (tivozanib) with a number of different companies, we believe that AVEO’s unique expertise in cancer biology and commitment to translational medicine offer the best chance for realizing the benefit that KRN951 may have for cancer patients.”